…is a screening test to prevent cervical cancer, which is convenient and accurate. Samples can be easily collected at home, and the test takes just 1 minute.Colon Cancer Screening Test : It uses FIT (fecal immunochemical …
…ish tomorrow's standard-of-care to cure cancer and infectious diseases, today announced the first patient dosed of their first-in-human, phase 1/2 study, GaLuCi(TM). The first patient was screened and dosed at the Austra…
…w's standard-of-care treatments to cure cancer and infectious diseases, today announced having obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting a novel DNA damage repair (DDR) pat…
…neering and Chula Medicine co-invent an innovative device for a rapid and accurate gastrointestinal cancer detection hoping to foster preventive medicine and reduce the number of cancer patients.Many types of cancers, es…
… standard for diagnosing and monitoring colorectal cancer and for diagnosis and surveillance of inflammatory bowel disease", says Maurizio Vecchi, Gastroenterology and Endoscopy Unit, Foundation IRCCS Ca' Granda Ospedale…
…ystem to target a complicated abdominal cancer using carefully shaped high-definition pencil beam scanning.The Varian ProBeam uses sophisticated imaging to see, adapt, and deliver treatment to the designated site, using …
…a and Australia etc.APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types, targeting patients with non-small cell lung cancer, thyroid cancer…
… of the most mutated oncogenes in human cancers. The prevalent G12C mutation drives tumor growth and metastasis and has become an important validated target for therapy especially in lung and colorectal cancer. Targeting…
… diagnostics company that has developed innovative technologies that transform patient care by providing effective precision diagnostics using liquid biopsy. Using its XNA technology it has developed a highly-sensitive, …
…atory biomarkers in advanced urothelial cancer- Overall efficacy data, and analyses of brain metastases and HRQoL for tepotinib[1] from largest ongoing study in NSCLC harboring METex14 skipping- Long-term follow-up data …
…atients to visit Bumrungrad was to seek cancer treatment, with the highest numbers of patients being from Myanmar and the United Arab Emirates. Cancer is the leading cause of death among people around the world and the n…
…y company, today announced data for its innovative investigational agents and investigational uses of marketed medicines to be presented at the American Society of Clinical Oncology (ASCO) ASCO20 Virtual Scientific Progr…
…ting. These abstracts represent several innovative modalities and mechanisms that have the potential to advance treatment across a range of difficult-to-treat cancers. The meeting will be held virtually from May 29-31."W…
…pecialty innovator - including bringing innovative medicines to markets with high unmet medical needs Not intended for UK-based mediaMerck, a leading science and technology company, today announced that ERBITUX(R) (cetux…
… leading manufacturer of targeted liver cancer therapies, today announced a collaboration with MIM Software Inc., a leading global provider of practical imaging solutions in the fields of radiation oncology, radiology, n…
…mechanisms targeting difficult-to-treat cancers will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31–June 4, Chicago, IL, US. New data will be presented for BAVENCIO(R)* (avel…
…ng Action Together: Improving Access to Innovative Cancer Medicines for ASEAN PatientsIn the countries that form the Association of South East Asian Nations (ASEAN), cancer is a rapidly growing disease. As with everywher…
…n previously untreated, advanced kidney cancer - New and updated data for bifunctional immunotherapy M7824 - Results from Phase II trials for tepotinib, including in EGFR TKI-resistant NSCLC - Additional pipeline data fe…
…ty in advanced NSCLC and HPV-associated cancers for investigational bifunctional immunotherapy, M7824 - Encouraging interim analysis of Phase II data in NSCLC sub-population for c-Met inhibitor, tepotinib - Record number…
…ndam and Naureen Starling, Institute of Cancer Research, London and Royal Marsden Hospital, London, UK, for their proposal: "Characterizing the evolution of metastatic colorectal cancer (mCRC) and its immune microenviron…
…ata validate potential in hard-to-treat cancers and highlight progress of the JAVELIN clinical development program - First data in mTNBC for ATR inhibitor (M6620) from Merck KGaA, Darmstadt, Germany's comprehensive portf…
…ata validate potential in hard-to-treat cancers and highlight progress of the JAVELIN clinical development program - First stand-alone data in mTNBC for ATR inhibitor (M6620) from Merck's comprehensive portfolio in DNA d…
- Cancer deaths in women are expected to increase to 5.5 million by 2030 Merck, a leading science and technology company, and the American Cancer Society (ACS) today released a report that shows all four of the top cause…
…inning proposals, which focus on breast cancer, colorectal cancer and lung cancer, were selected from a total of 405 applications representing 49 countries, following a comprehensive review by an expert scientific steeri…
